Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Chemotherapy For Pancreatic Cancer Strengthened By Vitamin A

XTALKS VITALS NEWS

Chemotherapy

Gemcitabine chemotherapy was paired with vitamin A, and the researchers noted both a reduction in cancer cell proliferation and invasion of surrounding tissue.

Share this!

May 26, 2016 | by Sarah Massey, M.Sc.

By combining chemotherapy and vitamin A, researchers have successfully reduced pancreatic cancer cell proliferation Tweet: Combining #chemotherapy and vitamin A reduced #pancreaticcancer proliferation http://ctt.ec/8ofYw+. Pancreatic cancer is one of the deadliest forms of the disease, with a survival rate of just 3 percent.

Traditional cancer treatment strategies – including chemotherapy and radiotherapy – are relatively ineffective against pancreatic cancer. While surgery has a higher success rate at removing the tumor tissue, the cancer has most often already metastasized by the time a diagnosis is made.

To develop a new approach to pancreatic cancer treatment, researchers at QMUL's Barts Cancer Institute focused on a new drug target: stromal cells. Up to 80 percent of pancreatic cancer tissue is made up of stromal cells, which surround and communicate with the cancer cells. These relatively-normal cells have a major impact on the progression of the pancreatic tumor, making them a key target for new cancer therapies.

Using both cell cultures and mice models, the researchers tested a combined therapy targeting both the cancerous tissue, and the surrounding stromal cells. Gemcitabine chemotherapy was paired with vitamin A, and the researchers noted both a reduction in cancer cell proliferation and invasion of surrounding tissue.

“This is the first time that we have combined vitamin A with chemotherapy for pancreatic cancer,” said Professor Hemant Kocher from QMUL's Barts Cancer Institute. “The results are so promising that we're now taking this into a clinical trial.”



By targeting both cell types, the researchers believe that multiple cell signaling pathways used by cancer cells to spread, could be interrupted. If the cancer cells are unable to communicate with the surrounding stromal cells, the tumor is unable to grow as aggressively as it would in the absence of treatment.

“Pancreatic cancer is extremely hard to treat by chemotherapy, so this finding is important because vitamin A targets the non-cancerous tissue and makes the existing chemotherapy more effective, killing the cancer cells and shrinking tumors,” said Kocher. “This could potentially be applicable to other cancers because if we try to understand the cancer as a whole, including its surrounding tissue, we may be able to develop new and better treatments.”

As a result of the preclinical studies, the researchers have now launched a clinical trial, STARPAC, to test the effectiveness of the combination therapy in patients. The trial – led by Barts Cancer Institute's Centre for Experimental Cancer Medicine – is currently recruiting participants.

“The majority of experimental work was done as part of my PhD project, and I am excited that our hard work in the laboratory is now being tested in the form of a clinical trial,” said QMUL PhD student Elisabete Carapuça. “We hope that it will benefit patients facing this awful disease.”


Keywords: Pancreatic Cancer, Clinical Trial, Combination Therapy


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.